- Browse by Author
Browsing by Author "Lavoie Smith, Ellen M."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Development and Preliminary Testing of the Collaboration for Innovation in Mentoring Survey: An Instrument of Nursing PhD Mentorship Quality(Elsevier, 2021) Smith, Asa B.; Umberfield, Elizabeth; Granner, Josephine R.; Harris, Melissa; Liestenfeltz, Bradley; Shuman, Clayton; Lavoie Smith, Ellen M.; School of NursingBackground: High-quality PhD nursing student mentorship facilitates student and program success. Extant literature recommends evaluating and improving mentorship to foster optimal PhD student development. However, a comprehensive measure capturing all aspects of mentorship salient to PhD nursing student wellbeing and success is not available. Objectives: The purpose of this pilot study was to develop a new instrument - the Collaboration for Leadership and Innovation in Mentoring (CLIM) - for quantifying important components of PhD student mentorship in nursing, and to preliminarily test its psychometric properties (content validity, sensitivity, test-retest reliability). Design: The study employed a cross-sectional design. Setting: The CLIM instrument was administered to nursing PhD students at a public state university in the United States. Participants: Sixteen nursing PhD students at various stages in their degree progression completed the instrument. Methods: PhD nursing students developed unique items based on qualitative data collected by the University using an Appreciative Inquiry framework. Seven nursing and non-nursing experts with experience in PhD mentorship evaluated content validity. After revisions, the final 44-item instrument was administered at two time points (one month apart) to allow assessment of test-retest reliability. Test-retest reliability was evaluated using Spearman-rank correlations and data from students with ≥1 year of experience with their mentor. Results: Response rates were 94% for both administrations (n = 16). The instrument's overall Content Validity Index (CVI) was 0.91 (p = 0.05). Test-retest analyses resulted in high correlations (r = 0.91, p < 0.001), further supporting reliability of the CLIM instrument. Conclusions: Preliminary evidence suggests that the CLIM instrument is a reliable instrument of PhD mentorship in nursing. However, additional testing in larger and more diverse graduate student populations is needed to evaluate internal consistency reliability, among other psychometric properties.Item Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update(ASCO, 2020-10) Loprinzi, Charles L.; Lacchetti, Christina; Bleeker, Jonathan; Cavaletti, Guido; Chauhan, Cynthia; Hertz, Daniel L.; Kelley, Mark R.; Lavino, Antoinette; Lustberg, Maryam B.; Paice, Judith A.; Schneider, Bryan P.; Lavoie Smith, Ellen M.; Smith, Mary Lou; Smith, Thomas J.; Wagner Johnston, Nina; Hershman, Dawn L.; Pediatrics, School of MedicinePURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS The search strategy identified 257 new references, which led to a full-text review of 87 manuscripts. A total of 3 systematic reviews, 2 with meta-analyses, and 28 primary trials for prevention of CIPN in addition to 14 primary trials related to treatment of established CIPN, are included in this update. RECOMMENDATIONS The identified data reconfirmed that no agents are recommended for the prevention of CIPN. The use of acetyl-l-carnitine for the prevention of CIPN in patients with cancer should be discouraged. Furthermore, clinicians should assess the appropriateness of dose delaying, dose reduction, substitutions, or stopping chemotherapy in patients who develop intolerable neuropathy and/or functional impairment. Duloxetine is the only agent that has appropriate evidence to support its use for patients with established painful CIPN. Nonetheless, the amount of benefit from duloxetine is limited.